Selected Publications

Freyer, C. W., Carulli, A., Gier, S., Ganetsky, A., Timlin, C., Schuster, M., Babushok, D., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Mangan, J. K., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K., Smith, J., Stadtmauer, E. A., Loren, A. W.: Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide Leuk Lymphoma : 1-9,2022.

Pratz, K. W., Panayiotidis, P., Recher, C., Wei, X., Jonas, B. A., Montesinos, P., Ivanov, V., Schuh, A. C., DiNardo, C. D., Novak, J., Pejsa, V., Stevens, D., Yeh, S. P., Kim, I., Turgut, M., Fracchiolla, N., Yamamoto, K., Ofran, Y., Wei, A. H., Bui, C. N., Benjamin, K., Kamalakar, R., Potluri, J., Mendes, W., Devine, J., Fiedler, W.: Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia Blood Cancer J 12 (4): 71,2022.

Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S. P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., Döhner, H.: Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine J Clin Oncol 40 (8): 855-865,2022.

Perl, A. E., Pratz, K. W.: Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy Cancer J 28 (1): 14-20,2022.

Pratz, K. W., Chai, X., Xie, J., Yin, L., Nie, X., Montez, M., Iantuono, E., Downs, L., Ma, E.: Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective Pharmacoeconomics : 2022.

Matthews, A. H., Perl, A. E., Luger, S. M., Loren, A. W., Gill, S. I., Porter, D. L., Babushok, D. V., Maillard, I., Carroll, M. P., Frey, N. V., Hexner, E., Martin, M. E., McCurdy, S. R., Stadtmauer, E. A., Paralkar, V. R., Jordan Bruno, X., Hwang, W. T., Margolis, D., Pratz, K. W.: Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia Blood Adv : 2022.

Konopleva, M., Thirman, M. J., Pratz, K. W., Garcia, J. S., Recher, C., Pullarkat, V., Kantarjian, H. M., DiNardo, C. D., Dail, M., Duan, Y., Chyla, B., Potluri, J., Miller, C. L., Wei, A. H.: Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia Clin Cancer Res : 2022.

Jonas, B. A., Wei, A. H., Recher, C., DiNardo, C. D., Jang, J. H., Pratz, K., Panayiotidis, P., Montesinos, P., Yeh, S. P., Ivanov, V., Fiedler, W., Yamauchi, T., Duan, Y., Mendes, W., Potluri, J., Tews, B., Ofran, Y.: Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia Am J Hematol : 2022.

Hatch, R. V., Freyer, C. W., Carulli, A., Redline, G., Babushok, D. V., Frey, N. V., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Porter, D. L., Pratz, K. W., Stadtmauer, E. A., Loren, A. W.: Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant J Oncol Pharm Pract 28 (4): 892-897,2022.

Graveno, M. E., Carulli, A., Freyer, C. W., Mangan, B. L., Nietupski, R., Loren, A. W., Frey, N. V., Porter, D. L., Gill, S. I., Hexner, E. O., Luger, S. M., Martin, M. E., McCurdy, S. R., Perl, A. E., Babushok, D. V., Pratz, K. W.: Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia Leuk Lymphoma : 1-6,2022.

Academic Contact Information

3400 Civic Center Blvd.
South Pavilion Room 12-155
Philadelphia, PA 19104
Patient appointments: 800-789-7366